CDMO - December 5, 2016
Recipharm enters new collaboration
Recipharm is entering into a collaboration with Laccure AB for the commercial manufacture and delivery of Laccure Pessary. The new product, which has been developed to help women suffering from bacterial vaginosis, will be manufactured, packaged and distributed globally from Recipharm’s facility in Karlskoga that specialises in the production of semi-solid products. Over the past […]
CDMO - November 2, 2016
Recipharm invests in its Italian API facility
Recipharm has announced an investment of over €1.2 million to enhance its small scale GMP active pharmaceutical ingredient (API) development and manufacturing capabilities in Paderno Dugnano, Italy. The investment, which is in response to growing demand for Recipharm’s custom synthesis and early phase API manufacturing capabilities, has seen the opening of a new GMP kilo […]
CDMO - October 19, 2016
Recipharm to open new GLP bioanalysis laboratory in Uppsala
Recipharm has announced a 5 million SEK investment into a new GLP (Good Laboratory Practice) compliant bioanalysis laboratory at its development facility in Uppsala, Sweden, in response to growing customer demand. The investment will see the opening of a 500 square metre purpose-built facility in November 2016, which will become the largest GLP bioanalysis laboratory of […]
In a new job - August 6, 2016
Recipharm appoints new General Manager
The Swedish CDMO Recipharm has appointed Ann Flodin as General Manager of its wholly owned new subsidiary Recipharm Laboratories in Research Triangle Park, North Carolina, USA, formerly Cirrus Pharmaceuticals. Following the acquisition of Kemwell’s US development business in April 2016, Ann Flodin will be responsible for managing daily operations in Recipharm in Research Triangle Park and will focus […]
Acquisition - April 16, 2016
Recipharm creates global CDMO through new acquisitions
Swedish CDMO Recipharm continues to expand. Most recently the company acquired Kemwell’s pharmaceutical CDMO businesses. In February Recipharm acquired privately owned Italian CDMO Mitim, adding important technology in the filling of injectable beta lactams with sales to the US and European markets. The transaction is valued at an enterprise value of EUR 68 million. The […]
Acquisition - February 24, 2016
Recipharm to acquire Mitim Srl for SEK 640 million
Recipharm AB announces that it has entered into an agreement to acquire Italian CDMO, Mitim Srl adding scale and capabilities to the group. Mitim is currently owned by a private Italian family and is specialised in the filling of injectable beta lactam products. It is located in Brescia close to Recipharm’s existing operations in Northern Italy. Highlights • Adds […]
